Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation

1991 ◽  
Vol 33 (2) ◽  
pp. 128-132 ◽  
Author(s):  
Claudio Fortis ◽  
Elisabetta Ferrero ◽  
Mauro Biffi ◽  
Silvia Heltai ◽  
Carlo Besana ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Renal Cancer ◽  
Ex Vivo ◽  
Interleukin 2 ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
Recombinant Interleukin 2 ◽  
Cells Cultured

Treatment of Metastatic Renal Cell Carcinoma with Recombinant Interleukin-2 in Combination with Vinblastine or Lymphokine-Activated Killer Cells

1993 ◽  
Vol 150 (3) ◽  
pp. 814-820 ◽  
Author(s):  
J. Philip Kuebler ◽  
Robert P. Whitehead ◽  
David L. Ward ◽  
George P. Hemstreet ◽  
Edward C. Bradley
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
Recombinant Interleukin 2

Continuous infusion of recombinant interleukin-2 and lymphokine-activated killer cells in refractory malignancies

1989 ◽  
Vol 17 (5-6) ◽  
pp. 455-458 ◽  
Author(s):  
Neal P. Christiansen ◽  
B. J. Kennedy ◽  
Augusto C. Ochoa ◽  
Keith M. Skubitz ◽  
Fritz H. Bach
Keyword(s):  
Continuous Infusion ◽  
Interleukin 2 ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
Recombinant Interleukin 2

Interstitial Nephritis in a Patient Receiving Adoptive Immunotherapy with Recombinant Interleukin-2 and Lymphokine-Activated Killer Cells

1991 ◽  
Vol 11 (6) ◽  
pp. 489-492 ◽  
Author(s):  
Donald A. Feinfeld ◽  
Vivette D’Agati ◽  
Janice P. Dutcher ◽  
Steven B. Werfel ◽  
Robert I. Lynn ◽  
...  
Keyword(s):  
Interstitial Nephritis ◽  
Adoptive Immunotherapy ◽  
Interleukin 2 ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
Recombinant Interleukin 2

In vivo generation of lymphokine-activated killer cells by sensitization with interleukin 2-producing syngeneic T-lymphoma cells

1988 ◽  
Vol 112 (1) ◽  
pp. 220-225 ◽  
Author(s):  
Takashi Nishimura ◽  
Yasushi Uchiyama ◽  
Yoshiyuki Hashimoto
Keyword(s):  
Interleukin 2 ◽  
Lymphokine Activated Killer Cells ◽  
Lymphoma Cells ◽  
Killer Cells ◽  
T Lymphoma Cells ◽  
T Lymphoma

Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-? in oral cancer patients

1992 ◽  
Vol 12 (4) ◽  
pp. 289-299 ◽  
Author(s):  
Kazunori Yoneda ◽  
Tetsuya Yamamoto ◽  
Eisaku Ueta ◽  
Tokio Osaki
Keyword(s):  
Oral Cancer ◽  
Cancer Patients ◽  
Low Dose ◽  
Interleukin 2 ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
Oral Cancer Patients

scholarly journals Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E rosette-depleted bone marrow

Blood ◽  
1987 ◽  
Vol 70 (6) ◽  
pp. 1893-1903 ◽  
Author(s):  
CA Keever ◽  
K Welte ◽  
T Small ◽  
J Levick ◽  
M Sullivan ◽  
...  
Keyword(s):  
Bone Marrow ◽  
T Cell ◽  
T Lymphocytes ◽  
Nk Cells ◽  
Peripheral Blood ◽  
Interleukin 2 ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
Lak Activity

Abstract During the early period following bone marrow transplantation before the immune system has reached full functional maturity, unprimed, nonspecific lytic systems may play a critical role as antiviral or antitumor effectors. The reconstitution of cells with this potential is of particular importance in recipients of bone marrow that has been depleted of mature T lymphocytes to prevent graft v host disease (GVHD). We examined the recovery of natural killer (NK) cells and interleukin 2 (IL 2)-augmented lymphokine-activated killer cells (LAK) in 48 patients at various intervals following transplantation of bone marrow depleted of mature cellular elements by treatment with soybean agglutinin and sheep RBCs (SBA-E- BMT). We found normal levels of both NK and LAK activity as early as 3 weeks following SBA-E- BMT. When compared with cells from controls, NK and LAK precursors from transplant recipients appeared to be activated in vivo in that freshly isolated peripheral blood mononuclear cells (PBMCs) from patients had an elevated cytolytic activity toward NK-insensitive targets and a more rapid response to activation by IL 2. In patients as well as controls, both LAK precursors and LAK effectors lacked antigens present on mature T lymphocytes (CD3, CD4, or CD8) but expressed antigens present on NK cells (CD2, CD16, and NKH1A). The LAK cells did not lyse either donor or host peripheral blood T cell targets. The activity of NK effectors but not LAK precursors survived the in vivo total body irradiation used for pretransplant conditioning in three patients studied. LAK precursors could be demonstrated as early as 18 days following transplant at a time when the bone marrow contained primarily donor- derived cells. Little or no LAK activity could be generated from cells of the SBA-E- BM graft itself, suggesting that LAK precursors differentiate rapidly from more primitive progenitors in the marrow graft. Thus, our data indicate that the NK and LAK lytic systems are among the earliest activities to recover during immune reconstitution following T cell-depleted BMTs.

Sign in / Sign up

Export Citation Format

Share Document